+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Avanir Pharmaceuticals Inc - Strategic SWOT Analysis Review

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Avanir Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - The publisher's summarization of the company's business strategy.
  • SWOT analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Avanir Pharmaceuticals Inc (Avanir), a subsidiary of Otsuka Pharmaceutical Co Ltd. is a biopharmaceutical company that focuses on the research, development, and commercialization of medical and pharmaceutical treatments for central nervous system disorders. The company's lead product include Nuedexta, a medication used for the treatment of pseudobulbar affect (PBA). The company's pipeline product include AVP-786 intended for the treatment of agitation in Alzheimer's disease, residual schizophrenia, intermittent explosive disorder, disinhibition in dementia and traumatic brain injury behavioral dysfunction, among others. Avanir is headquartered in Aliso Viejo, California, the US.

Avanir Pharmaceuticals Inc Key Recent Developments

Jul 28, 2021: Avanir Pharmaceuticals joins California Life Sciences
Apr 19, 2021: Avanir joins Decentralized Trials & Research Alliance (DTRA) as a founding member to advance access to clinical trials

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors' business structure and strategies with the publisher's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Avanir Pharmaceuticals Inc - Key Facts
  • Avanir Pharmaceuticals Inc - Key Employees
  • Avanir Pharmaceuticals Inc - Key Employee Biographies
  • Avanir Pharmaceuticals Inc - Major Products and Services
  • Avanir Pharmaceuticals Inc - History
  • Avanir Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Avanir Pharmaceuticals Inc - Business Description
  • Avanir Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Avanir Pharmaceuticals Inc - Strengths
  • Avanir Pharmaceuticals Inc - Weaknesses
  • Avanir Pharmaceuticals Inc - Opportunities
  • Avanir Pharmaceuticals Inc - Threats
  • Avanir Pharmaceuticals Inc - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Avanir Pharmaceuticals Inc, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Jul 28, 2021: Avanir Pharmaceuticals joins California Life Sciences
  • Apr 19, 2021: Avanir joins Decentralized Trials & Research Alliance (DTRA) as a founding member to advance access to clinical trials
Section 5 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Avanir Pharmaceuticals Inc, Key Facts
  • Avanir Pharmaceuticals Inc, Key Employees
  • Avanir Pharmaceuticals Inc, Key Employee Biographies
  • Avanir Pharmaceuticals Inc, Major Products and Services
  • Avanir Pharmaceuticals Inc, History
  • Avanir Pharmaceuticals Inc, Subsidiaries
  • Avanir Pharmaceuticals Inc, Key Competitors
  • Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Avanir Pharmaceuticals Inc, Recent Deals Summary
List of Figures
  • Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Avanir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Nektar Therapeutics
  • Sagent Pharmaceuticals Inc
  • Aegerion Pharmaceuticals Inc
  • Auxilium Pharmaceuticals LLC
  • Halozyme Therapeutics Inc
  • Vivus LLC
  • Acorda Therapeutics Inc